Andrew Foxley, BA of AstraZeneca @AstraZeneca discusses a phase III trial of capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer.
Read here: https://meetinglibrary.asco.org/record/191881/abstract
Advertisement